Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure.

G. G. Knowlen, Mark D Kittleson, R. F. Nachreiner, G. E. Eyster

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The plasma aldosterone concentration (PAC) among clinical status groups of 23 dogs with chronic heart failure was compared at various times after diagnosis of the problem. Eighteen dogs admitted in New York Heart Association (NYHA) class IV clinical status had significant elevations in PAC (P<0.0001), when compared with clinically normal dogs. Five dogs admitted in NYHA class III status and 4 dogs that responded with a change to NYHA class III status had significant elevations in PAC (P<0.01), when compared with clinically normal dogs. In patients with NYHA class IV status, the PAC was significantly greater (P<0.01) than in patients in NYHA class III status. For patients with the poorest prognosis, ie, severe signs of NYHA class IV status, the PAC was not markedly different, when compared with that for patients with a favorable prognosis, ie, recent onset of signs of NYHA class IV status. Patients treated with captopril had significantly lower PAC after therapy (P<0.01), whereas patients treated with hydralazine had significantly higher PAC (P<0.05) after therapy. It was concluded that heart failure in the dog increases PAC, most likely because of renin-angiotensin-aldosterone-system activation, and that the increase is related directly to the clinical status of the patient. Further, it was concluded that treatment of dogs in heart failure with captopril causes a decrease in circulating PAC, whereas treatment with hydralazine causes an increase in circulating PAC.

Original languageEnglish (US)
Pages (from-to)991-996
Number of pages6
JournalJournal of the American Veterinary Medical Association
Volume183
Issue number9
StatePublished - Nov 1 1983
Externally publishedYes

Fingerprint

aldosterone
heart failure
Aldosterone
Heart Failure
Dogs
dogs
heart
Hydralazine
Captopril
prognosis
angiotensins
renin
therapeutics
Therapeutics
Renin-Angiotensin System

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure. / Knowlen, G. G.; Kittleson, Mark D; Nachreiner, R. F.; Eyster, G. E.

In: Journal of the American Veterinary Medical Association, Vol. 183, No. 9, 01.11.1983, p. 991-996.

Research output: Contribution to journalArticle

@article{beaa456e782b44808f7eeaf9c30abeec,
title = "Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure.",
abstract = "The plasma aldosterone concentration (PAC) among clinical status groups of 23 dogs with chronic heart failure was compared at various times after diagnosis of the problem. Eighteen dogs admitted in New York Heart Association (NYHA) class IV clinical status had significant elevations in PAC (P<0.0001), when compared with clinically normal dogs. Five dogs admitted in NYHA class III status and 4 dogs that responded with a change to NYHA class III status had significant elevations in PAC (P<0.01), when compared with clinically normal dogs. In patients with NYHA class IV status, the PAC was significantly greater (P<0.01) than in patients in NYHA class III status. For patients with the poorest prognosis, ie, severe signs of NYHA class IV status, the PAC was not markedly different, when compared with that for patients with a favorable prognosis, ie, recent onset of signs of NYHA class IV status. Patients treated with captopril had significantly lower PAC after therapy (P<0.01), whereas patients treated with hydralazine had significantly higher PAC (P<0.05) after therapy. It was concluded that heart failure in the dog increases PAC, most likely because of renin-angiotensin-aldosterone-system activation, and that the increase is related directly to the clinical status of the patient. Further, it was concluded that treatment of dogs in heart failure with captopril causes a decrease in circulating PAC, whereas treatment with hydralazine causes an increase in circulating PAC.",
author = "Knowlen, {G. G.} and Kittleson, {Mark D} and Nachreiner, {R. F.} and Eyster, {G. E.}",
year = "1983",
month = "11",
day = "1",
language = "English (US)",
volume = "183",
pages = "991--996",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "9",

}

TY - JOUR

T1 - Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure.

AU - Knowlen, G. G.

AU - Kittleson, Mark D

AU - Nachreiner, R. F.

AU - Eyster, G. E.

PY - 1983/11/1

Y1 - 1983/11/1

N2 - The plasma aldosterone concentration (PAC) among clinical status groups of 23 dogs with chronic heart failure was compared at various times after diagnosis of the problem. Eighteen dogs admitted in New York Heart Association (NYHA) class IV clinical status had significant elevations in PAC (P<0.0001), when compared with clinically normal dogs. Five dogs admitted in NYHA class III status and 4 dogs that responded with a change to NYHA class III status had significant elevations in PAC (P<0.01), when compared with clinically normal dogs. In patients with NYHA class IV status, the PAC was significantly greater (P<0.01) than in patients in NYHA class III status. For patients with the poorest prognosis, ie, severe signs of NYHA class IV status, the PAC was not markedly different, when compared with that for patients with a favorable prognosis, ie, recent onset of signs of NYHA class IV status. Patients treated with captopril had significantly lower PAC after therapy (P<0.01), whereas patients treated with hydralazine had significantly higher PAC (P<0.05) after therapy. It was concluded that heart failure in the dog increases PAC, most likely because of renin-angiotensin-aldosterone-system activation, and that the increase is related directly to the clinical status of the patient. Further, it was concluded that treatment of dogs in heart failure with captopril causes a decrease in circulating PAC, whereas treatment with hydralazine causes an increase in circulating PAC.

AB - The plasma aldosterone concentration (PAC) among clinical status groups of 23 dogs with chronic heart failure was compared at various times after diagnosis of the problem. Eighteen dogs admitted in New York Heart Association (NYHA) class IV clinical status had significant elevations in PAC (P<0.0001), when compared with clinically normal dogs. Five dogs admitted in NYHA class III status and 4 dogs that responded with a change to NYHA class III status had significant elevations in PAC (P<0.01), when compared with clinically normal dogs. In patients with NYHA class IV status, the PAC was significantly greater (P<0.01) than in patients in NYHA class III status. For patients with the poorest prognosis, ie, severe signs of NYHA class IV status, the PAC was not markedly different, when compared with that for patients with a favorable prognosis, ie, recent onset of signs of NYHA class IV status. Patients treated with captopril had significantly lower PAC after therapy (P<0.01), whereas patients treated with hydralazine had significantly higher PAC (P<0.05) after therapy. It was concluded that heart failure in the dog increases PAC, most likely because of renin-angiotensin-aldosterone-system activation, and that the increase is related directly to the clinical status of the patient. Further, it was concluded that treatment of dogs in heart failure with captopril causes a decrease in circulating PAC, whereas treatment with hydralazine causes an increase in circulating PAC.

UR - http://www.scopus.com/inward/record.url?scp=0020858999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020858999&partnerID=8YFLogxK

M3 - Article

C2 - 12002592

AN - SCOPUS:0020858999

VL - 183

SP - 991

EP - 996

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 9

ER -